ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

AbbVie licenses CD47 inhibitor from I-Mab

by Lisa M. Jarvis
September 11, 2020 | APPEARED IN VOLUME 98, ISSUE 35

 

AbbVie will pay I-Mab $180 million for access outside China to lemzoparlimab, an anti-CD47 antibody in development for several types of cancer. Many cancer cells display CD47 on their surfaces to evade detection by white blood cells called macrophages. CD47 has long been a target of interest to cancer-drug developers, but inhibitors can cause anemia—a side effect that I-Mab claims lemzoparlimab avoids. AbbVie paid the Chinese firm another $20 million because of positive Phase I results for the antibody.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment